Company
Our mission is to create real hopes
through innovative new drug developments
History
  • HOME
  • Company
  • History
2017~PRESENT Growth and Leap of Pinotbio
  • 2023
    12
    Received the MOTIE Award for ‘2023 IP-R&D Outstanding Institution’
    11
    Received the KoreaBIO President’s Award for

    ‘2023 Bio Innovation & Growth Corporation’
    09
    Selected for KDDF’s National Novel Drug Development Grant (ADC)
    05
    Selected for MOTIE’s National Research Grant for Biotech Technology

    Development (ADC)
    04
    Strategic Investment (Lotte Biologics, KR)

    Venture Capital Funding (Pre-IPO)
    03
    Strategic Investment (Ahn-Gook Pharm, KR)
    01
    Entered joint development of ADCs (Bridge Biotherapeutics, KR)

    Passed KOSDAQ Technology Evaluation
  • 2022
    12
    Entered joint development of next-gen ADC treatment
    (Ahn-Gook Pharm, KR)
    10
    Strategic Investment (Celltrion, KR)

    Entered into licensing agreement for the use of the PINOT-ADC™ Platform and joint development of ADCs (Celltrion, KR)
    08
    Jointly awarded KDDF government R&D research grant for expanding the foundation of novel drug development (ProEn Therapeutics, KR)
    06
    Entered into licensing agreement for the use of the PINOT-ADC™ Platform (ConjugateBio, USA)
    05
    Entered additional joint development (Aptamer Group, UK)
    02
    Entered joint development of ADCs (Hecto Healthcare, KR)
  • 2021
    06
    Entered joint development of repebody-drug conjugate
    (ProEn Therapeutics, KR)

    Entered joint development of aptamer-drug conjugate
    (Aptamer Group, UK)

    Entered into licensing agreement for NTX-301 in non-oncology indication
    (AkiraBio, USA)
    05
    NTX-301 Phase 1/2 clinical trial approval in Australia
    (solid cancer, ovarian cancer, and bladder cancer)
    03
    Strategic Investment (ST Pharm, KR)
    02
    Started the clinical trial of NTX-301 (blood cancer)
  • 2020
    12
    NTX-101 Phase 1 IND approved in Korea
    11
    Venture Capital Funding (Series C)
    07
    Established US subsidiary (Pinotbio North America, Inc.)
    04
    Changed company name (Bionetix Inc. → Pinotbio Inc.)
    03
    Appointed IPO representative (NH Investment & Securities, KB Securities)
    02
    NTX-301 Phase 1/2 (blood cancer) IND approved in the US
  • 2019
    12
    Venture Capital Funding (Series B)

    Completed the phase 1a clinical trial of NTX-301 (solid cancer) in the US
    06
    Completed the preclinical development of NTX-101
    04
    Completed the preclinical development of NTX-301 (blood cancer)
    01
    Started the phase 1a clinical trial of NTX-301 (solid cancer) in the US
  • 2018
    11
    Started the preclinical development of NTX-301 (blood cancer)
    10
    NTX-301 Phase 1/2 (solid cancer) IND approved in US (NCI CTEP Program)

    Secured the exclusive license for NTX-301
    09
    Venture Capital Funding (Series A)
    02
    Research Institute established and certified
  • 2017
    12
    Started the development of PINOT-ADC™ platform
    11
    Venture Capital Funding(2nd Seed Round)
    06
    Started the preclinical development of NTX-301(solid cancer)
    03
    Venture Capital Funding(1st Seed Round)

    Started the preclinical development of NTX-101
    02
    Bionetix Inc. Established